Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection.
We evaluated the efficacy of amphotericin B (1.5mg/kg/day), voriconazole (60mg/kg/day) and posaconazole (60mg/kg/day) in a murine model of systemic infection caused by Neoscytalidium dimidiatum. All the treatments were able to prolong survival and to reduce the tissue burden in the spleen and kidneys of infected mice. Neither voriconazole nor posaconazole improved the results achieved with amphotericin B.
Ruíz-Cendoya
Mery
M
Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain.
Madrid
Hugo
H
Pastor
Javier
J
Guarro
Josep
J
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001203:Ascomycota / Q000187:drug effects* / Q000302:isolation & purification; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D007668:Kidney / Q000382:microbiology; D008297:Male; D051379:Mice; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D009503:Neutropenia; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology; D013154:Spleen / Q000382:microbiology; D016019:Survival Analysis; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D000666:Amphotericin B; D065819:Voriconazole